EICHORPublic-registry site landscape for NCT04433546, “Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).”, a Acute Respiratory Distress Syndrome study sponsored by PhaseBio Pharmaceuticals Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04433546 (registry record) |
| Study title | Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). |
| Official title | A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of Pemziviptadil (PB1046), a Sustained-Release VIP (Vasoactive Intestinal Peptide) ANalogue, in Hospitalized COVID-19 Patients at HiGh Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study) |
| Sponsor | PhaseBio Pharmaceuticals Inc. |
| Condition(s) | Acute Respiratory Distress Syndrome; Coronavirus; Hypoxic Respiratory Failure; Hypoxemic Respiratory Failure |
| Phase | PHASE2 |
| Listed sites | 4 |
| Intervention(s) | Pemziviptadil (PB1046), Low Dose (10 mg) Control |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04433546.
Eichor generates a preliminary site-risk snapshot for NCT04433546 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
